USPTO 2015–2025 USPTO PatentsView US Corporation

Roche Molecular Systems, Inc.

USPTO PatentsView assignee record - 395 granted patents across 67 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr).

RSS updates for this company

The verdict

According to USPTO PatentsView, Roche ranks #1,083 of 49,997 tracked US assignees by granted-patent volume, with 395 patents across 67 technology areas.

#1,083
of 49,997 US assignees by volume
Top 5%
by Innovation Score (57.8/100)
11.7
avg claims per patent
-19%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R1083 · US Corporation #1,083 · 395 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-WIDE · INNOV-PAR · CLAIMS-PAR · TYPE-USCORP · VEL-DOWN · BOOK-FULL

  • GRANTS-MID 395 grants
  • TOP-DECILE #1,083/49,997
  • PHOTO-FINISH Digital Global Systems
  • CPC-WIDE C12Q · 67 areas
  • INNOV-PAR 57.8/100
  • CLAIMS-PAR 11.7 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-DOWN -19% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Digital Global Systems, Inc. (±1 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Roche

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Roche's Innovation Score is 57.8/100 (top 5% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

How Roche's grant cadence moved

Between 2020–2024, Roche Molecular Systems, Inc. received 171 grants versus 210 in 2015–2019 (-19% equal-window velocity, below median growth). Across complete PatentsView years, output peaked in 2018 at 55 grants and bottomed in 2022 at 26. Lead class C12Q accounts for 55.7% of the portfolio across 67 subclasses. Volume neighbours: Mstar Semiconductor, Inc. (#1,079) and Stats ChipPAC Pte. Ltd. (#1,087).

Roche's three-year grant acceleration

From 2019–2021 to 2022–2024, Roche Molecular Systems, Inc. moved from 117 to 89 grants (0.76x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #1,957. See the growth leaderboard.

Who files at Roche's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Roche holds 395 patents at rank #1,083, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Roche

By rank, the assignees closest to #1,083 in granted patent volume.

Leaders in C12Q (Measuring OR Testing Processes Involving Enzymes)

Other assignees with the most granted patents in Roche's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Roche, neither rank-band nor same-CPC leaders (those blocks stay above).

Roche's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

58 Top 5% higher than 95% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

102030405060 20152016201720182019202020212022202320242025 14
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Roche Molecular Systems, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 32 8.1%
2016 54 13.7%
2017 34 8.6%
2018 55 13.9%
2019 35 8.9%
2020 50 12.7%
2021 32 8.1%
2022 26 6.6%
2023 30 7.6%
2024 33 8.4%
2025partial year 14 3.5%

Which technologies does Roche Molecular Systems, Inc. patent most?

Top 15 of 67 technology areas

Where it ranks

Overall rank by patents

#1,083

of 49,997 tracked assignees

Innovation Score

57.8 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Roche Molecular Systems, Inc.'s patent record in context - here's where to go next.

  • Roche Molecular Systems, Inc.'s lead technology class is C12Q (Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Micr), 55.7% of its portfolio - see every assignee active in that class. Explore C12Q
  • Ranked #1,083 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Roche Molecular Systems, Inc. against Mstar Semiconductor, Inc., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 57.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.